Archive - March 2022
FDA Approves Locametz (kit for the preparation of gallium Ga 68 gozetotide injection) for PSMA PET Imaging in Patients with Prostate Cancer
FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Huma and AstraZeneca collaborate to advance digital innovation
NHS contacting five million people for fourth COVID-19 vaccination
FDA approves BMS’s Opdualag for metastatic or unresectable melanoma
Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments
Closing the supply chain visibility gap
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome